The Maastricht Study

The Maastricht Study - The Maastricht Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34961

Enrollment

10000

Registered

2010-10-18

Start date

2010-11-02

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: participant should be an inhabitant of Maastricht and Heuvelland region and between 40 to 75 years of age. Moreover, all participants need to have normal mental capacities and be legally not restricted in any way. Addititional inclusion criteria for the diabetes subgroup are diagnosed type 2 diabetes according to GP criteria or fasting circulating levels of glucose of 6.1 mmol/L or more or circulating levels of 10.0 mmol/L or more after 2-hours glucose load (oral glucose tolerance test).[33]

Exclusion criteria

Exclusion criteria: None, except for nursing home residency, hospital or psychiatric institute admission and (severe) cognitive limitations which interferes with any of the procedures to obtain informed consent according to the Helsinki declaration.

Design outcomes

Primary

Measure	Time frame
The covering structure of the Maastricht Study can then be described along 7 separate research lines that are highly interrelated: A. Diabetes, pre-diabetes and the metabolic syndrome Focus: the implementation of novel techniques to study glucose tolerance status / the metabolic syndrome in relation to the development of both micro- and macro cardiovascular disease. B. Cardiovascular Imaging Focus: the implementation of techniques to study structure and function of the central and peripheral circulation and, their relationship with any of the study endpoints C. Neurological Diseases Focus: the implementation of techniques to study structure and function of the central and peripheral nervous system and, their relationship with any of the study endpoints D. Respiratory Diseases and other co-morbidities Focus: the implementation of spirometry and ambulatory respiratory monitoring, gastro-intestinal disease and, their relationship with any of the study endpoints E. Lifestyle & Behavioural Studies Focus: the implementation of questionnaires and function tests that provide information about diet, exercise and illness behaviour / coping mechanisms in chronic disease and, their relationship with study endpoints (including muscular-skeletal diseases). F. Public Health Focus: the collection of demographic as well as socio-demographic data; in addition a repetitive morbidity and mortality surveillance will be held on all participants G. Biomarker Collection & Biobanking Focus: establishment of a biobank, which includes blood-, urine-, faeces- and DNA - sampling. In addition to the collection of microbial nasal swabs and respiratory air samples. Endpoints & Determinants The study can be described in term of study endpoints which are based upon on the International Classification of Diseases version 10 (ICD-10 codes) and include: A: Diabetes, pre-diabetes and the metabolic syndrome - E11 Type 2 Diabetes - Subcutaneous and visceral fat - Ecto	—

Measure

Time frame

The covering structure of the Maastricht Study can then be described along 7 separate research lines that are highly interrelated: A. Diabetes, pre-diabetes and the metabolic syndrome Focus: the implementation of novel techniques to study glucose tolerance status / the metabolic syndrome in relation to the development of both micro- and macro cardiovascular disease. B. Cardiovascular Imaging Focus: the implementation of techniques to study structure and function of the central and peripheral circulation and, their relationship with any of the study endpoints C. Neurological Diseases Focus: the implementation of techniques to study structure and function of the central and peripheral nervous system and, their relationship with any of the study endpoints D. Respiratory Diseases and other co-morbidities Focus: the implementation of spirometry and ambulatory respiratory monitoring, gastro-intestinal disease and, their relationship with any of the study endpoints E. Lifestyle & Behavioural Studies Focus: the implementation of questionnaires and function tests that provide information about diet, exercise and illness behaviour / coping mechanisms in chronic disease and, their relationship with study endpoints (including muscular-skeletal diseases). F. Public Health Focus: the collection of demographic as well as socio-demographic data; in addition a repetitive morbidity and mortality surveillance will be held on all participants G. Biomarker Collection & Biobanking Focus: establishment of a biobank, which includes blood-, urine-, faeces- and DNA - sampling. In addition to the collection of microbial nasal swabs and respiratory air samples. Endpoints & Determinants The study can be described in term of study endpoints which are based upon on the International Classification of Diseases version 10 (ICD-10 codes) and include: A: Diabetes, pre-diabetes and the metabolic syndrome - E11 Type 2 Diabetes - Subcutaneous and visceral fat - Ecto

—

Secondary

Measure	Time frame
not applicable (yet)	—

Countries

Netherlands

Outcome results